Intestinal Pseudo-Obstruction Treatment Global Market Report 2024

Description

“Intestinal Pseudo-Obstruction Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on intestinal pseudo-obstruction treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for intestinal pseudo-obstruction treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The intestinal pseudo-obstruction treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Drug Class: Antibiotics; Antidepressants; Antidiarrheals
2) By Treatment: Medication; Surgery; Diet; Decompression; Other Treatments
3) By Route Of Administration: Oral; Intravenous; Other Route Of Administrations
4) By Diagnosis: Physical Examination; Biopsy; Blood Test; Gastric Emptying Tests; Imaging Tests; Other Diagnosis
5) By End User: Clinic; Hospitals; Other End Users
Companies Mentioned: F. Hoffmann-La Roche AG; Merck Sharp & Dohme Corp; Bayer AG; Sanofi S.A.; AstraZeneca plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Intestinal pseudo-obstruction (IPO) treatment addresses a rare gastrointestinal motility disorder exhibiting symptoms akin to a mechanical bowel obstruction, even in the absence of a physical blockage. The goals of treating intestinal pseudo-obstruction involve symptom relief, enhancement of intestinal motility, complication management, and overall improvement in quality of life.

The primary drug classes encompassed in IPO treatment comprise antibiotics, antidepressants, and antidiarrheals. Antibiotics represent a potent category of medications employed for combating bacterial infections in both human and animal patients. Diverse treatment modalities, such as medication, surgery, dietary adjustments, decompression, and others, are administered via various routes, including oral, intravenous, among others. Multiple diagnostic approaches, including physical examinations, biopsies, blood tests, gastric emptying tests, imaging studies, among others, are utilized by a range of end users, including clinics, hospitals, and other healthcare facilities.

The intestinal pseudo-obstruction market research report is one of a series of new reports from The Business Research Company that provides intestinal pseudo-obstruction market statistics, including intestinal pseudo-obstruction industry global market size, regional shares, competitors with a intestinal pseudo-obstruction market share, detailed intestinal pseudo-obstruction market segments, market trends and opportunities and any further data you may need to thrive in the intestinal pseudo-obstruction industry. This intestinal pseudo-obstruction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intestinal pseudo-obstruction treatment market size has grown strongly in recent years. It will grow from $22.06 billion in 2023 to $23.46 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to increased recognition and diagnosis, advancements in medical imaging, advancements in gastrointestinal motility testing, global healthcare access.

The intestinal pseudo-obstruction treatment market size is expected to see strong growth in the next few years. It will grow to $29.04 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to research and drug development, telemedicine and remote monitoring, patient education and support, reimbursement policies. Major trends in the forecast period include advanced gastrointestinal motility testing, immunomodulatory therapies, nutritional interventions, data analytics and ai.

The increasing prevalence of Parkinson's disease is anticipated to be a significant driver for the expansion of the intestinal pseudo-obstruction (IPO) treatment market in the foreseeable future. Parkinson's disease is a neurodegenerative condition primarily affecting dopamine-producing neurons in the substantia nigra region of the brain. The heightened incidence of IPO in individuals with Parkinson's disease is attributed to its impact on the enteric nervous system, leading to gastrointestinal dysmotility, potentially resulting in conditions like megacolon or acute colonic pseudo-obstruction. For instance, in December 2022, according to the Parkinson's Foundation, a U.S.-based non-profit organization, there has been a notable increase in Parkinson's disease diagnoses, with approximately 90,000 Americans being identified annually, representing a substantial 50% surge from previous estimates. Moreover, it is projected that by 2030, the global population with Parkinson's disease will reach 1.2 million. Consequently, the escalating cases of Parkinson's disease serve as a driving force for the growth of the intestinal pseudo-obstruction treatment market.

The escalating incidence of cancer is anticipated to be a significant catalyst for the expansion of the intestinal pseudo-obstruction (IPO) treatment market in the foreseeable future. Cancer is characterized by the uncontrolled growth and spread of certain cells within the body. Lifestyle factors such as sedentary behavior, poor dietary habits, and tobacco use contribute to an elevated risk of developing cancer. In cases of IPO occurring alongside cancer, the primary focus of treatment involves addressing the underlying cancer, which can lead to an improvement or resolution of the gastrointestinal symptoms associated with pseudo-obstruction. For instance, in May 2021,according to the National Library of Medicine, a US-based medical resource, the global burden of cancer is projected to surge by 47% from 2020, resulting in an estimated 28.4 million cases by 2040. Consequently, the increasing incidence of cancer plays a pivotal role in driving the growth of the intestinal pseudo-obstruction (IPO) treatment market.

The low incidence rate of intestinal pseudo-obstruction (IPO) is projected to act as a constraint on the growth of the IPO treatment market in the foreseeable future. This relatively low occurrence of IPO can hinder market expansion. As of July 2023, according to the National Library of Medicine, a US-based biomedical library, the annual incidence of acute intestinal pseudo-obstruction is estimated to be approximately 100 cases per 100,000 inpatient admissions. Consequently, the low incidence rate serves as a limiting factor for the growth of the intestinal pseudo-obstruction (IPO) treatment market.

Leading players in the intestinal pseudo-obstruction treatment market are increasingly embracing plant-based remedies to bolster their market presence. Plant-derived supplements offer a promising avenue for mitigating the risk of bowel obstruction through their ability to facilitate regular bowel movements and mitigate inflammation. A notable example is Enzymedica Inc., a US-based pharmaceutical company, which introduced Gut Motility in August 2021. This groundbreaking plant-based supplement is designed to enhance gastrointestinal motility and gastric emptying. Its formulation combines artichoke leaf extract, ginger root CO2 extract, and apple cider vinegar, marking a significant milestone in nutraceutical innovation. The cornerstone of Gut Motility is ProDigest, a triple-standardized blend of artichoke leaf extract and ginger root CO2 extract, supported by clinical evidence demonstrating its efficacy in promoting healthy digestive transit. Furthermore, the inclusion of apple cider vinegar, sourced from US-grown apples, helps maintain a balanced pH in the digestive tract, optimizing metabolic processes.

In May 2023, Ironwood Pharmaceuticals, a pharmaceutical company headquartered in the United States, completed the acquisition of VectivBio Holding AG for an undisclosed sum. This strategic move is poised to bolster Ironwood's innovation capabilities and expand its portfolio, ultimately reshaping the benchmark for care in the field of gastrointestinal (GI) medicine. The acquisition will also propel advancements in the treatment of GI disorders, with VectivBio Holding AG, a clinical-stage biotechnology company based in Switzerland, specializing in the treatment of severe and rare gastrointestinal conditions, including Intestinal Pseudo-Obstruction (IPO).

Major players in the intestinal pseudo-obstruction treatment market are F. Hoffmann-La Roche AG, Merck Sharp & Dohme Corp, Bayer AG, Sanofi S.A., AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Amgen PLC, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Mylan N.V., Biogen Inc., Penn Medicine, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Inc., Dr. Reddy's Laboratories Ltd., Allergan PLC, Torrent Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Melinta Therapeutics LLC, Tetraphase Pharmaceuticals Inc., Callisto Pharmaceuticals Inc.

North America was the largest region in the intestinal pseudo-obstruction treatment market in 2023. The regions covered in intestinal pseudo-obstruction (IPO) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the intestinal pseudo-obstruction (IPO) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intestinal pseudo-obstruction (IPO) treatment market consists of revenues earned by providing entities by providing surgical interventions, decompression and nutrition support. The market value includes the value of related goods sold by the service provider or included within the service offering. The intestinal pseudo-obstruction (IPO) treatment market also includes sales of narcotics, laxatives and pro-kinetics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12341

1. Executive Summary

2. Intestinal Pseudo-Obstruction Treatment Market Characteristics

3. Intestinal Pseudo-Obstruction Treatment Market Trends And Strategies

4. Intestinal Pseudo-Obstruction Treatment Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Intestinal Pseudo-Obstruction Treatment Market Size and Growth

5.1. Global Intestinal Pseudo-Obstruction Treatment Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Intestinal Pseudo-Obstruction Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Intestinal Pseudo-Obstruction Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Intestinal Pseudo-Obstruction Treatment Market Segmentation

6.1. Global Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Antibiotics
Antidepressants
Antidiarrheals
6.2. Global Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Medication
Surgery
Diet
Decompression
Other Treatments
6.3. Global Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Intravenous
Other Route Of Administrations
6.4. Global Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Physical Examination
Biopsy
Blood Test
Gastric Emptying Tests
Imaging Tests
Other Diagnosis
6.5. Global Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Clinic
Hospitals
Other End Users

7. Intestinal Pseudo-Obstruction Treatment Market Regional And Country Analysis

7.1. Global Intestinal Pseudo-Obstruction Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Intestinal Pseudo-Obstruction Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Intestinal Pseudo-Obstruction Treatment Market

8.1. Asia-Pacific Intestinal Pseudo-Obstruction Treatment Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Intestinal Pseudo-Obstruction Treatment Market

9.1. China Intestinal Pseudo-Obstruction Treatment Market Overview
9.2. China Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Intestinal Pseudo-Obstruction Treatment Market

10.1. India Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Intestinal Pseudo-Obstruction Treatment Market

11.1. Japan Intestinal Pseudo-Obstruction Treatment Market Overview
11.2. Japan Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Intestinal Pseudo-Obstruction Treatment Market

12.1. Australia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Intestinal Pseudo-Obstruction Treatment Market

13.1. Indonesia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Intestinal Pseudo-Obstruction Treatment Market

14.1. South Korea Intestinal Pseudo-Obstruction Treatment Market Overview
14.2. South Korea Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Intestinal Pseudo-Obstruction Treatment Market

15.1. Western Europe Intestinal Pseudo-Obstruction Treatment Market Overview
15.2. Western Europe Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Intestinal Pseudo-Obstruction Treatment Market

16.1. UK Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Intestinal Pseudo-Obstruction Treatment Market

17.1. Germany Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Intestinal Pseudo-Obstruction Treatment Market

18.1. France Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Intestinal Pseudo-Obstruction Treatment Market

19.1. Italy Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Intestinal Pseudo-Obstruction Treatment Market

20.1. Spain Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Intestinal Pseudo-Obstruction Treatment Market

21.1. Eastern Europe Intestinal Pseudo-Obstruction Treatment Market Overview
21.2. Eastern Europe Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Intestinal Pseudo-Obstruction Treatment Market

22.1. Russia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Intestinal Pseudo-Obstruction Treatment Market

23.1. North America Intestinal Pseudo-Obstruction Treatment Market Overview
23.2. North America Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Intestinal Pseudo-Obstruction Treatment Market

24.1. USA Intestinal Pseudo-Obstruction Treatment Market Overview
24.2. USA Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Intestinal Pseudo-Obstruction Treatment Market

25.1. Canada Intestinal Pseudo-Obstruction Treatment Market Overview
25.2. Canada Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Intestinal Pseudo-Obstruction Treatment Market

26.1. South America Intestinal Pseudo-Obstruction Treatment Market Overview
26.2. South America Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Intestinal Pseudo-Obstruction Treatment Market

27.1. Brazil Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Intestinal Pseudo-Obstruction Treatment Market

28.1. Middle East Intestinal Pseudo-Obstruction Treatment Market Overview
28.2. Middle East Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Intestinal Pseudo-Obstruction Treatment Market

29.1. Africa Intestinal Pseudo-Obstruction Treatment Market Overview
29.2. Africa Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Intestinal Pseudo-Obstruction Treatment Market Competitive Landscape And Company Profiles

30.1. Intestinal Pseudo-Obstruction Treatment Market Competitive Landscape
30.2. Intestinal Pseudo-Obstruction Treatment Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche AG
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Merck Sharp & Dohme Corp
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Bayer AG
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Sanofi S.A.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. AstraZeneca plc
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Intestinal Pseudo-Obstruction Treatment Market Other Major And Innovative Companies

31.1. GSK plc
31.2. Takeda Pharmaceutical Company Limited
31.3. Amgen PLC
31.4. Boehringer Ingelheim International GmbH
31.5. Teva Pharmaceutical Industries Ltd.
31.6. Astellas Pharma Inc.
31.7. Mylan N.V.
31.8. Biogen Inc.
31.9. Penn Medicine
31.10. Sun Pharmaceutical Industries Ltd.
31.11. Aurobindo Pharma Ltd
31.12. Cipla Inc.
31.13. Dr. Reddy's Laboratories Ltd.
31.14. Allergan plc
31.15. Torrent Pharmaceuticals Limited

32. Global Intestinal Pseudo-Obstruction Treatment Market Competitive Benchmarking

33. Global Intestinal Pseudo-Obstruction Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Intestinal Pseudo-Obstruction Treatment Market

35. Intestinal Pseudo-Obstruction Treatment Market Future Outlook and Potential Analysis

35.1 Intestinal Pseudo-Obstruction Treatment Market In 2028 - Countries Offering Most New Opportunities
35.2 Intestinal Pseudo-Obstruction Treatment Market In 2028 - Segments Offering Most New Opportunities
35.3 Intestinal Pseudo-Obstruction Treatment Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer